Equities

VolitionRX Ltd

VolitionRX Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.8398
  • Today's Change0.030 / 3.68%
  • Shares traded148.52k
  • 1 Year change+24.41%
  • Beta1.1815
Data delayed at least 15 minutes, as of Nov 21 2024 19:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

  • Revenue in USD (TTM)1.29m
  • Net income in USD-29.87m
  • Incorporated1998
  • Employees110.00
  • Location
    VolitionRX Ltd1489 West Warm Springs Road, Suite 110HENDERSON 89014United StatesUSA
  • Phone+1 (646) 650-1351
  • Fax+65 6333-7235
  • Websitehttps://volition.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Citius Oncology Inc0.001.93m70.59m--4.090.142836.51--0.2420.2420.006.930.00------3.25--3.35--------------0.036------535.30------
Bioatla Inc11.00m-81.82m71.55m65.00--3.12--6.50-1.70-1.700.22840.47510.103----169,230.80-76.61-48.72-103.22-57.35-----743.79-6,651.71----0.00-------15.95---37.01--
Vistagen Therapeutics Inc875.70k-39.57m72.67m45.00--0.7595--82.99-1.30-1.300.02893.440.0121----22,453.85-54.69-62.84-58.94-68.03-----4,518.12-5,768.52----0.00--568.10--50.44---18.91--
P3 Health Partners Inc1.48bn-102.69m72.90m400.00--0.2739--0.0494-0.753-0.75311.080.7441.71--12.283,691,575.00-28.94---83.29---2.720.1781-16.95-56.93---12.940.3358--20.6770.5878.61---11.20--
Werewolf Therapeutics Inc3.39m-62.12m73.08m45.00--0.8022--21.58-1.50-1.500.08192.040.0214--1.0672,042.55-39.26---42.91-------1,834.55------0.2228--21.60--30.56------
Ovid Therapeutics Inc631.56k-32.50m73.81m25.00--0.968--116.87-0.4598-0.45980.00891.070.0056----15,789.00-28.55-20.78-31.34-23.27-----5,146.15-56.16----0.00---73.93--3.38---17.14--
Regencell Bioscience Holdings Ltd0.00-4.30m74.17m12.00--9.02-----0.3306-0.33060.000.63160.00----0.00-41.44-56.31-42.99-77.51------------0.00------26.73------
PDS Biotechnology Corp0.00-40.56m74.56m25.00--3.39-----1.17-1.170.000.59750.00----0.00-73.98-51.63-98.74-59.00-----------19.130.5286-------5.11------
VolitionRX Ltd1.29m-29.87m74.60m110.00------58.02-0.3623-0.36230.0155-0.23280.0837--7.4111,689.36-196.61-111.92---196.20-----2,348.71-10,793.31---104.15----153.04---16.68--29.13--
Armata Pharmaceuticals Inc5.47m-41.36m75.62m66.00------13.83-1.24-1.240.1312-1.410.0518--1.0282,833.34-39.21-59.78-116.66-72.70-----756.59-1,113.72----1.90---17.77---87.03--184.10--
Aerovate Therapeutics Inc0.00-84.61m76.79m51.00--0.954-----2.99-2.990.002.790.00----0.00-72.99---81.83--------------0.00-------46.61------
ESSA Pharma Inc0.00-27.67m76.79m50.00--0.5957-----0.6257-0.62570.002.900.00----0.00-19.33-23.01-19.81-23.67------------0.00------24.27------
Fibrobiologics Inc0.00-17.78m77.64m10.00--27.76-----0.8864-0.88640.000.08070.00----0.00-149.60---225.38--------------0.0403-------272.15------
Chimerix Inc159.00k-83.59m79.14m72.00--0.5829--497.76-0.9351-0.93510.00181.510.0008--1.922,208.33-43.54-30.45-48.29-34.092.52---52,574.84-442.93----0.00---99.04-46.24-147.68---13.24--
CervoMed Inc10.07m-11.95m79.57m8.00--1.74--7.90-1.60-1.601.355.530.3305----1,258,319.00-39.22-53.67-43.28-58.89-----118.68-949.54----0.00------86.07------
Data as of Nov 21 2024. Currency figures normalised to VolitionRX Ltd's reporting currency: US Dollar USD

Institutional shareholders

18.90%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 30 Sep 20249.00m9.77%
Lagoda Investment Management LPas of 30 Sep 20246.10m6.62%
Geode Capital Management LLCas of 30 Sep 2024730.45k0.79%
The Vanguard Group, Inc.as of 30 Sep 2024622.95k0.68%
BlackRock Fund Advisorsas of 30 Sep 2024445.19k0.48%
Silverberg Bernstein Capital Management LLCas of 30 Sep 2024142.62k0.16%
SSgA Funds Management, Inc.as of 30 Sep 2024123.92k0.14%
UBS Securities LLCas of 30 Sep 2024114.13k0.12%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 202489.30k0.10%
Ground Swell Capital LLCas of 30 Sep 202445.96k0.05%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.